SUPPLEMENT TO:

Population Pharmacokinetic-Pharmacodynamic Model of Nirogacestat Effects on B-Cell Maturation Antigen in Healthy Subjects

Todd Shearer, PhD,¹ Rex L. Williams Jr, PhD¹ Mark Johnson, PhD¹
Ewa Cendrowicz, PhD,² Cathrine Leonowens, PharmD, FCCP³
Margaret Smith, BA¹ Todd Baughman, MSC¹
Caroline J. Breitbach, PhD¹ Shinta Cheng, MD, PhD¹

¹SpringWorks Therapeutics, Stamford, CT, USA
²ICON BioAnalytical Laboratories, Assen, The Netherlands
³Nuventra Pharma Sciences, Durham, NC, USA

Presented at American Society of Clinical Oncology (ASCO) 2023 • June 2-6, 2023 • Chicago, IL.

Supplemental Figure 1. Plasma Cells Were Isolated From Whole Blood and Bone Marrow Aspirates for Determination of BCMA Receptor Density (MESF)

BCMA = B-cell maturation antigen; FSC-A = forward scatter area; FSC-H = forward scatter height; FSC-W = forward scatter width; MESF = molecules of equivalent soluble fluorochrome and is representative of the number of receptors detected on an individual cell; SSC-A = side scatter area

Supplemental Figure 2. Nirogacestat PK Model Diagnostic Plots

DV = dependent variable; PRED = population predictions; IPRED = individual predictions; CWRES = conditional weighted residuals

Supplemental Figure 3. Exposure-Response Model Diagnostic Plots

DV = dependent variable; PRED = population predictions; IPRED = individual predictions; CWRES = conditional weighted residuals